Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
5suwrY9JaQDVsmy1
